Targeting dormant micrometastases: Rationale, evidence to date and clinical implications

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 2, 2016, Pages 126-137

  Hurst, Robert E ^a   Bastian, Anja ^b   Bailey Downs, Lora ^c   Ihnat, Michael A ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c DormaTarg Inc   (United States)

Author keywords

dormant cancer cells; micrometastatic cells; prevention

Indexed keywords

NEW DRUG;

CANCER CELL; CANCER SCREENING; CANCER STEM CELL; DORMANCY; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROMETASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR RECURRENCE; TUMOR XENOGRAFT;

EID: 84958058830     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015624277     Document Type: Review

References (72)

1. Almog N., (2010) Molecular mechanisms underlying tumor dormancy. Cancer Lett 294: 139-146
2. Bailey-Downs L., Thorpe J., Disch B., Bastian A., Hauser P., Farasyn T., et al. (2014) Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. PLoS One 9: e98624
3. Balar A., Milowsky M., (2015) Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development. Urol Clin North Am 42: 217-224
4. Barkan D., Green J., (2011) An in vitro system to study tumor dormancy and the switch to metastatic growth. J Vis Exp 54: e2914
5. Barkan D., Green J., Chambers A., (2010) Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 46: 1181-1188
6. Barkan D., Kleinman H., Simmons J., Asmussen H., Kamaraju A., Hoenorhoff M., et al. (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68: 6241-6250
7. Bender D., Sill M., Lankes H., Reyes H., Darus C., Delmore J., et al. (2015) A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138: 507-512
8. Caruana I., Savoldo B., Hoyos V., Weber G., Liu H., Kim E., et al. (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21: 524-529
9. Chong M., Lim J., Goh J., Sia M., Chan J., Teoh S., (2014) Cocultures of mesenchymal stem cells and endothelial cells as organotypic models of prostate cancer metastasis. Mol Pharm 11: 2126-2133
10. Cohen I., Murdoch A., Naso M., Marchetti D., Berd D., Iozzo R., (1994) Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res 54: 5771-5774
11. Coleman R., Sill M., Bell-Mcguinn K., Aghajanian C., Gray H., Tewari K., et al. (2015a) A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation-an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 137: 386-391
12. Coleman R., Sill M., Thaker P., Bender D., Street D., McGuire W., et al. (2015b) A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138: 30-35
13. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 381: 805-816
14. Dirven L., Van Den Bent M., Bottomley A., Van Der Meer N., Van Der Holt B., Vos M., et al. (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomized controlled phase II BELOB trial. Eur J Cancer 51: 1321-1330
15. Eggermont A., Chiarion-Sileni V., Grob J., Dummer R., Wolchok J., Schmidt H., et al. (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized, double-blind, phase III trial. Lancet Oncol 16: 522-530
16. El Touny L., Vieira A., Mendoza A., Khanna C., Hoenerhoff M., Green J., (2013) Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Invest 124: 156-168
17. Gao D., Nolan D., Mellick A., Bambino K., McDonnell K., Mittal V., (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195-198
18. Ghajar C., (2015) Metastasis prevention by targeting the dormant niche. Nat Rev Cancer 15: 238-247
19. Ghajar C., Peinado H., Mori H., Matei I., Evason K., Brazier H., et al. (2013) The perivascular niche regulates breast tumor dormancy. Nat Cell Biol 15: 807-817
20. Gotte M., Yip G., (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66: 10233-10237
21. Gray J., (2003) Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 4: 4-6
22. Guiro K., Patel S., Greco S., Rameshwar P., Arinzeh T., (2015) Investigating breast cancer cell behavior using tissue engineering scaffolds. PLoS One 10: e0118724
23. Hirte H., Lheureux S., Fleming G., Sugimoto A., Morgan R., Biagi J., et al. (2015) A phase II study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecol Oncol 138: 55-61
24. Hurst R., Hauser P., Kyker K., Heinlen J., Hodde J., Hiles M., et al. (2013) Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell 'dormancy'. PLoS One 8: e64181
25. Hurst R., Hauser P., You Y., Bailey-Downs L., Bastian A., Matthews S., et al. (2015) Identification of novel drugs to target dormant micrometastases. BMC Cancer 15: 404
26. Hurst R., Kamat C., Kyker K., Green D., Ihnat M., (2005) A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SISgel. Cancer Lett 217: 171-180
27. Iozzo R., (1995) Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest 73: 157-160
28. Izraely S., Sagi-Assif O., Klein A., Meshel T., Tsarfaty G., Pasmanik-Chor M., et al. (2011) The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. Int J Cancer 131: 1071-1082
29. Kenny H., Lal-Nag M., White E., Shen M., Chiang C., Mitra A., et al. (2015) Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun 6: 6220
30. Kim R., Avivar-Valderas A., Estrada Y., Bragado P., Sosa M., Aguirre-Ghiso J., et al. (2012) Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One 7: e35569
31. Kobayashi A., Okuda H., Xing F., Pandey P., Watabe M., Hirota S., et al. (2011) Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med 208: 2641-2655
32. Landreville S., Agapova O., Matatall K., Kneass Z., Onken M., Lee R., et al. (2012) Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18: 408-416
33. Lassman A., Pugh S., Gilbert M., Aldape K., Geinoz S., Beumer J., et al. (2015) Phase II trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol 17: 992-998
34. Leaf C., (2004) Why we're losing the war on cancer (and how to win it). Fortune 149: 76-88
35. Lin W., Rajbhandari N., Wagner K., (2014) Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies. Cancer Res 74: 2138-2143
36. Lu X., Mu E., Wei Y., Riethdorf S., Yang Q., Yuan M., et al. (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 20: 701-714
37. Machiels J., Haddad R., Fayette J., Licitra L., Tahara M., Vermorken J., et al. (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomized phase III trial. Lancet Oncol 16: 583-594
38. Makker V., Filiaci V., Chen L., Darus C., Kendrick J., Sutton G., et al. (2015) Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol 138: 24-29
39. Manjili M., (2014) The inherent premise of immunotherapy for cancer dormancy. Cancer Res 74: 6745-6749
40. Marlow R., Honeth G., Lombardi S., Cariati M., Hessey S., Pipili A., et al. (2013) A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res 73: 6886-6899
41. Marsden C., Wright M., Carrier L., Moroz K., Pochampally R., Rowan B., (2012) A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies. BMC Cancer 12: 10
42. Marshall J., Collins J., Nakayama J., Horak C., Liewehr D., Steinberg S., et al. (2012) Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst 104: 1306-1319
43. Melchior S., Corey E., Ellis W., Ross A., Layton T., Oswin M., et al. (1997) Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 3: 249-256
44. Mendoza A., Hong S., Osborne T., Khan M., Campbell K., Briggs J., et al. (2010) Modeling metastasis biology and therapy in real time in the mouse lung. J Clin Invest 120: 2979-2988
45. Milojkovic D., Apperley J., (2009) Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15: 7519-7527
46. Mitra A., Mishra L., Li S., (2015) EMT, CTCs and CSCs in tumor relapse and drug resistance. Oncotarget 6: 10697-10711
47. Moore K., Sill M., Tenney M., Darus C., Griffin D., Werner T., et al. (2015) A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: an NRG/Gynecologic Oncology Group trial. Gynecol Oncol 138: 513-518
48. Nash K., Phadke P., Navenot J., Hurst D., Accavitti-Loper M., Sztul E., et al. (2007) Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 99: 309-321
49. Osisami M., Keller E., (2013) Mechanisms of metastatic tumor dormancy. J Clin Med 2: 136-150
50. Pitz M., Eisenhauer E., Macneil M., Thiessen B., Easaw J., Macdonald D., et al. (2015) Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol 17: 1270-1274
51. Rabinovsky R., Uhr J., Vitetta E., Yefenof E., (2007) Cancer dormancy: lessons from a B-cell lymphoma and adenocarcinoma of the prostate. Adv Cancer Res 97: 189-202
52. Ranganathan A., Adam A., Zhang L., Guirre-Ghiso J., (2006) Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther 5: 729-735
53. Ross J., Huh D., Noble L., Tavazoie S., (2015) Identification of molecular determinants of primary and metastatic tumor reinitiation in breast cancer. Nat Cell Biol 17: 651-664
54. Sakamoto S., Inoue H., Ohba S., Kohda Y., Usami I., Masuda T., et al. (2015) New metastatic model of human small cell lung cancer by orthotopic transplantation in mice. Cancer Sci 106: 367-374
55. Singhal N., Mislang A., Karapetis C., Stephens S., Borg M., Woodman R., et al. (2015) Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer: an open-label phase II multicenter trial (COVeRT study). Anticancer Drugs 26: 1083-1088
56. Sosa M., Bragado P., Aguirre-Ghiso J., (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14: 611-622
57. Stokes M., Thompson D., Montoya E., Weinstein M., Winer E., Earle C., (2008) Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health 11: 213-220
58. Sun Y., Ma L., (2015) The emerging molecular machinery and therapeutic targets of metastasis. Trends Pharmacol Sci 36: 349-359
59. Sutherland R., Eddy H., Bareham B., Reich K., Vanantwerp D., (1979) Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 5: 1225-1230
60. Swain S., Baselga J., Kim S., Ro J., Semiglazov V., Campone M., et al. (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372: 724-734
61. Talmadge J., Fidler I., (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70: 5649-5669
62. Teicher B., Herman T., Holden S., Wang Y., Pfeffer M., Crawford J., et al. (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247: 1457-1461
63. Tivari S., Korah R., Lindy M., Wieder R., (2015) An in vitro dormancy model of estrogen-sensitive breast cancer in the bone marrow: a tool for molecular mechanism studies and hypothesis generation. J Vis Exp 100: e52672
64. Vescio R., Redfern C., Nelson T., Ugoretz S., Stern P., Hoffman R., (1987) In vivo -like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 84: 5029-5033
65. Viale A., Pettazzoni P., Lyssiotis C., Ying H., Sánchez N., Marchesini M., et al. (2014) Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514: 628-632
66. Voytik-Harbin S., (2001) Chapter 26 three-dimensional extracellular matrix substrates for cell culture. Cytometry 63: 561-581
67. Wang J., Mi J., Debernardi A., Vitte A., Emadali A., Meyer J., et al. (2015) A six-gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia. Oncotarget 6: 16527-16542
68. Weber G., (2013) Why does cancer therapy lack effective antimetastasis drugs? Cancer Lett 328: 207-211
69. Wheeler S., Clark A., Taylor D., Young C., Pillai V., Stolz D., et al. (2014) Spontaneous dormancy of metastatic breast cancer cells in an all-human liver microphysiologic system. Br J Cancer 111: 2342-2350
70. Xia J., Trock B., Gulati R., Mallinger L., Cooperberg M., Carroll P., et al. (2014) Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res 20: 5302-5310
71. Yang Y., Mauldin P., Ebeling M., Hulsey T., Liu B., Thomas M., et al. (2013) Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer 119: 1512-1520
72. Ying H., Kimmelman A., Lyssiotis C., Hua S., Chu G., Fletcher-Sananikone E., et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149: 656-670.